Navigation Links
Immunosyn Announces the Successful Completion of First Phase 'Proof of Concept Trial' in Europe for Treatment of Diabetic Ulcers With Biopharmeceutical SF-1019
Date:1/17/2008

LA JOLLA, Calif., Jan. 17 /PRNewswire-FirstCall/ -- Immunosyn Corporation (OTC Bulletin Board: IMYN) announced today that the first phase of a formal "Proof of Concept Trial" for the biopharmaceutical SF-1019 has been successfully completed in Europe for treatment of Diabetic Ulcers.

The Board of Immunosyn was advised as to the success of this important phase of the "Proof of Concept Trial" by Argyll Biotechnologies, LLC its strategic partner and largest shareholder. Argyll Biotechnologies is the developer and licensor of SF-1019, for which Immunosyn has been granted the world-wide rights to market, sell and distribute under an exclusive license agreement.

The primary purpose of the "Proof of Concept Trial" is to further evaluate the safety and efficacy of SF-1019 in the treatment of Diabetic Ulceration and its effect on Diabetic Polyneuropathy in Type 1 Diabetes Mellitus by both subcutaneous injection and by topical application.

Regarding the "Proof of Concept Trial," Professor Angus Dalgleish, MBBS, BSc, MD, FRCP, RACP, FRCPath, FMedSci, Chief Scientist and Consultant Medical Officer for Argyll Biotechnologies, LLC stated that, "This first very important phase in the development of SF-1019, which was undertaken at a European venue, has indicated that SF-1019 promotes wound healing and almost certainly induces growth factors." "When systemically delivered, SF-1019 has shown the rapid resolution of long standing chronic lesions which is very impressive. And the topical application of SF-1019, while showing promise, in that a 5mm deep wound became closed, needs, as expected, unlike the subcutaneous method, more short-term development in order to improve the delivery methodology," he added.

Clinical Director for Argyll Biotechnologies, David Maizels, MD, MSc, MRCS, LRCP, has also advised that, "Because of the positive results, which both the independent clinical team and I have observed during the first phase of the "Proof of Concept
'/>"/>

SOURCE Immunosyn Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine news :

1. Immunosyn Corporation Names Stephen Ferrone as CEO
2. Immunosyn Corporation to Begin Trading
3. Equity Research Firm Issued Unauthorized Report and Press Release on Immunosyn Corporation Today
4. HHS Announces $75 Million in Supplemental Funding to States for Pandemic Flu Preparedness
5. CRC Health Group Announces Acquisition of Bayside Marin Recovery Center, San Rafael
6. UHW Announces: Antelope Valley Hospital Caregivers and Board Vote to Ratify First Union Contract With SEIU UHW-West
7. HEI, Inc. Announces Sale of RFID Division Assets
8. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Zyloprim(R)
9. Mettler-Toledo International Inc. Announces Webcast of Presentation at Thomas Weisel Partners 2007 Healthcare Conference
10. Z Trim Announces Revocation of Gregory Halpern Severence Agreement
11. Brooke Franchise Corporation Announces Selected July Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/18/2014)... medical-testing device is being prepped to enter the ... diagnosis of certain diseases in remote areas, thanks ... of investigations aboard the International Space Station on ... space-tested concept of capillary flow to diagnose infectious ... Kelso, Ph.D., a researcher at Northwestern University in ...
(Date:4/18/2014)... of your worst memories? How did it make you ... a negative personal experience, such as how sad you ... emotional distress, especially when you can,t stop thinking about ... thinking about the context of the memories, rather than ... way to alleviate the negative effects of these memories, ...
(Date:4/18/2014)... French . ... medicine. A team led by Ludwik Leibler from the ... Didier Letourneur from the Laboratoire Recherche Vasculaire Translationnelle (INSERM/Universits ... the principle of adhesion by aqueous solutions of nanoparticles ... and tissues. This easy-to-use gluing method has been tested ...
(Date:4/17/2014)... identified the first genetic variant specifically associated with ... for around 10-15 per cent of all breast ... the breast cancer sub-type, called invasive lobular carcinoma, ... of this particular kind of breast cancer, which ... published today (Thursday) in the journal PloS ...
(Date:4/17/2014)... the April issue of Experimental Biology and ... Drs. Rex Gaskins and Paul Kenis in the ... of the University of Illinois Urbana-Champaign describe their ... reactions underlie a variety of cell functions including ... these crucial roles in regulating normal cellular behavior, ...
Breaking Medicine News(10 mins):Health News:Space-tested fluid flow concept advances infectious disease diagnoses 2Health News:Space-tested fluid flow concept advances infectious disease diagnoses 3Health News:New study suggests a better way to deal with bad memories 2Health News:New study suggests a better way to deal with bad memories 3Health News:Innovative strategy to facilitate organ repair 2Health News:Innovative strategy to facilitate organ repair 3Health News:First genetic link discovered to difficult-to-diagnose breast cancer sub-type 2Health News:First genetic link discovered to difficult-to-diagnose breast cancer sub-type 3Health News:Live cell imaging reveals distinct alterations of subcellular glutathione potentials 2
... June 11 On Wednesday the U.S. House of ... Relations Reauthorization Act, which creates a new "Office for ... and support efforts regarding "women,s empowerment" around the world. ... the Foreign Affairs Committee that this administration "will protect ...
... , NORTH HOLLYWOOD, Calif., June 10 IPC The Hospitalist Company, ... practice company, announced today that management is scheduled to present at ... 2009 in New York City. Adam Singer, M.D., Chairman and ... the conference. IPC,s presentation will take place at 3:15 P.M. ...
... Inc. (NYSE: CRE ) ("Care" or the "Company") ... of $0.17 per share of common stock for the first quarter ... common shareholders of record on June 23, 2009. , ... Inc. is a real estate investment and finance company investing in ...
... CJ Foundation for SIDS announced today the launch of their ... aiming to further raise public awareness about the importance of ... funds to support on-going SIDS research, education, and family bereavement ... that safe sleeping environments can cost less, be beautiful and ...
... short-term use during pregnancy should be safe, , WEDNESDAY, ... that women who experience morning sickness early in pregnancy ... symptoms. , The study, which included nearly 3,500 ... to treat gastrointestinal (GI) problems, found no significant increases ...
... Calif., June 10 ThermoGenesis Corp. (Nasdaq: KOOL ... storing adult stem cells, said today that J. Melville Engle, ... board of directors. His appointment brings the total number of ... than 30 years of management experience in the healthcare industry, ...
Cached Medicine News:Health News:IPC The Hospitalist Company, Inc. to Present at Jefferies 3rd Annual Healthcare Conference 2Health News:Care Investment Trust Inc. Announces Quarterly Dividend 2Health News:The CJ Foundation for SIDS Announces SLEEP IN SAFETY, GROW IN STYLE Initiative 2Health News:Morning Sickness Drug Gets Green Light in Study 2Health News:Morning Sickness Drug Gets Green Light in Study 3Health News:ThermoGenesis Appoints Chief Executive Officer J. Melville ('Mel') Engle to Board of Directors 2Health News:ThermoGenesis Appoints Chief Executive Officer J. Melville ('Mel') Engle to Board of Directors 3Health News:ThermoGenesis Appoints Chief Executive Officer J. Melville ('Mel') Engle to Board of Directors 4
(Date:1/14/2014)... , Jan. 14, 2014  Luminex Corporation (Nasdaq: ... for the fourth quarter of 2013 on Monday, February 3, ... release after the close of trading. (Logo: ... call to discuss the operating highlights and financial results for ...
(Date:1/14/2014)... The Brandeis Medical Center, led by Dr. Emmanuel Brandeis ... affordable laser tattoo removal experience with the advanced Astanza Duality laser ... high quality cosmetic services with cutting edge medical technology and offering ... California has seen a dramatic increase in the presence ...
(Date:1/14/2014)... -- Acumed,s new SLIC Screw System - a jointed ... place and insert the screw accurately - offers surgeons ... repair or reconstruction as it holds the bones reduced ... http://photos.prnewswire.com/prnh/20140114/MN45636 ) The SLIC Screw is ...
Breaking Medicine Technology:Luminex Corporation Fourth Quarter Earnings Release Scheduled for February 3, 2014 2Luminex Corporation Fourth Quarter Earnings Release Scheduled for February 3, 2014 3Beverly Hills Physician Features Tattoo Removal with the Astanza Duality Laser, Offers $99 Special 2Acumed introduces the Scapho-Lunate Inter Carpal (SLIC) Screw System 2Acumed introduces the Scapho-Lunate Inter Carpal (SLIC) Screw System 3
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products: